Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review
With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are...
Saved in:
Published in: | Hormone research in paediatrics Vol. 96; no. 6; p. 620 |
---|---|
Main Authors: | , , |
Format: | Journal Article |
Language: | English |
Published: |
Switzerland
01-11-2023
|
Subjects: | |
Online Access: | Get more information |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are glucose-lowering agents that inhibit the reabsorption of filtered glucose in the kidneys, thus promoting glucosuria. Because the glucose-lowering effect of SGLT2 inhibitors is achieved independently of insulin secretion, it has been speculated whether they could bridge the gap towards achieving glycaemic targets in individuals with type 1 diabetes.
Our main goal was to systematically map the current knowledge on the efficacy and safety of SGLT2 inhibitor use in adults with type 1 diabetes and present recent studies regarding the use of SGLT2 inhibitors in youth with type 1 diabetes. Using a scoping review approach, we searched MEDLINE to identify relevant clinical trials of SGLT2 inhibitors as adjunctive therapy to insulin in type 1 diabetes published from January 31, 2012, to January 31, 2022. We included the most relevant, large-scale, and long placebo-controlled clinical trials of SGLT2 inhibitors as an add-on therapy to insulin in adults with type 1 diabetes. Additionally, we included all relevant pilot studies evaluating the use of SGLT2 inhibitors as add-on therapy to insulin in youth with type 1 diabetes. We identified eight placebo-controlled clinical trials in adults with type 1 diabetes meeting our inclusion criteria and two relevant pilot studies in youth with type 1 diabetes. The clinical trials in adults with type 1 diabetes confirmed the efficacy of SGLT2 inhibitors as add-on therapy to insulin. However, this was associated with an increased incidence of diabetic ketoacidosis (DKA) versus placebo in all identified clinical trials. The two relevant pilot studies in youth with type 1 diabetes showed promising results of SGLT2 inhibitor use as an add-on therapy to insulin, especially when combined with a fully closed-loop system.
SGLT2 inhibitors, as an add-on therapy to insulin, improve glycaemic outcomes in adults with type 1 diabetes with a potential cost of increasing DKA risk. The use of add-on SGLT2 inhibitors to insulin shows promising results in youth with type 1 diabetes. Moreover, SGLT2 inhibitors as add-on therapy in combination with closed-loop insulin therapy could provide additional benefits in improving glycaemic control. The current role of SGLT2 inhibitors as an adjunct therapy to insulin in individuals with type 1 diabetes is yet to be determined. |
---|---|
AbstractList | With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant proportion of individuals with type 1 diabetes do not reach recommended glycaemic goals. Sodium-glucose co-transporter-2 (SGLT2) inhibitors are glucose-lowering agents that inhibit the reabsorption of filtered glucose in the kidneys, thus promoting glucosuria. Because the glucose-lowering effect of SGLT2 inhibitors is achieved independently of insulin secretion, it has been speculated whether they could bridge the gap towards achieving glycaemic targets in individuals with type 1 diabetes.
Our main goal was to systematically map the current knowledge on the efficacy and safety of SGLT2 inhibitor use in adults with type 1 diabetes and present recent studies regarding the use of SGLT2 inhibitors in youth with type 1 diabetes. Using a scoping review approach, we searched MEDLINE to identify relevant clinical trials of SGLT2 inhibitors as adjunctive therapy to insulin in type 1 diabetes published from January 31, 2012, to January 31, 2022. We included the most relevant, large-scale, and long placebo-controlled clinical trials of SGLT2 inhibitors as an add-on therapy to insulin in adults with type 1 diabetes. Additionally, we included all relevant pilot studies evaluating the use of SGLT2 inhibitors as add-on therapy to insulin in youth with type 1 diabetes. We identified eight placebo-controlled clinical trials in adults with type 1 diabetes meeting our inclusion criteria and two relevant pilot studies in youth with type 1 diabetes. The clinical trials in adults with type 1 diabetes confirmed the efficacy of SGLT2 inhibitors as add-on therapy to insulin. However, this was associated with an increased incidence of diabetic ketoacidosis (DKA) versus placebo in all identified clinical trials. The two relevant pilot studies in youth with type 1 diabetes showed promising results of SGLT2 inhibitor use as an add-on therapy to insulin, especially when combined with a fully closed-loop system.
SGLT2 inhibitors, as an add-on therapy to insulin, improve glycaemic outcomes in adults with type 1 diabetes with a potential cost of increasing DKA risk. The use of add-on SGLT2 inhibitors to insulin shows promising results in youth with type 1 diabetes. Moreover, SGLT2 inhibitors as add-on therapy in combination with closed-loop insulin therapy could provide additional benefits in improving glycaemic control. The current role of SGLT2 inhibitors as an adjunct therapy to insulin in individuals with type 1 diabetes is yet to be determined. |
Author | Hropot, Tim Dovc, Klemen Battelino, Tadej |
Author_xml | – sequence: 1 givenname: Tim surname: Hropot fullname: Hropot, Tim organization: Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia – sequence: 2 givenname: Tadej surname: Battelino fullname: Battelino, Tadej email: tadej.battelino@mf.uni-lj.si, tadej.battelino@mf.uni-lj.si organization: Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Ljubljana, Slovenia, tadej.battelino@mf.uni-lj.si – sequence: 3 givenname: Klemen surname: Dovc fullname: Dovc, Klemen organization: Department of Pediatric Endocrinology, Diabetes and Metabolic Diseases, University Children's Hospital, Ljubljana, Slovenia |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36279850$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j81KAzEYAIMottYefAHJC0Tzs_nzVlathULBrueSfBs10t0syVbp2yuopzkMDMwFOu1THxC6YvSGMWlvKaWSayXFCZoypQThhqsJmpfy8aOoMNoyfY4mQnFtjaRTtNmmNh46stwfIJWA60Sa7PoypDyGTDhe9e_RxzHlgmOPm-MQMMP30fkwhnKHF3gLaYj9G34OnzF8XaKzV7cvYf7HGXp5fGjqJ7LeLFf1Yk1AKDsSVwVqg-BguWRQ8cob8OBaa8BQkNYpQbVg4AVY7QzllrcMTCsV01JZymfo-rc7HHwX2t2QY-fycfd_xr8BdYtNjw |
CitedBy_id | crossref_primary_10_1161_CIRCULATIONAHA_123_065517 crossref_primary_10_1016_j_biopha_2024_116650 |
ContentType | Journal Article |
Copyright | 2022 S. Karger AG, Basel. |
Copyright_xml | – notice: 2022 S. Karger AG, Basel. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1159/000527653 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Anatomy & Physiology |
EISSN | 1663-2826 |
ExternalDocumentID | 36279850 |
Genre | Journal Article Review |
GroupedDBID | --- 0R~ 0~5 0~B 30W 327 3O. 3V. 4.4 53G 7RV 7X7 88E 8AO 8FI 8FJ AAYIC ABJNI ABPAZ ABUWG ACGFS ACPRK ACPSR ADBBV AENEX AEYAO AFJJK AFKRA AFRAH AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BENPR BKEYQ BKNYI BPHCQ BVXVI CAG CCPQU CGR COF CUY CVF CYUIP DU5 E0A EBS ECM EIF EJD EMOBN EX3 F5P FB. FYUFA HMCUK HZ~ IY7 K9- KUZGX M0R M1P NAPCQ NPM O1H O9- OVD PQQKQ PROAC PSQYO RKO RXVBD SV3 TEORI UJ6 UKHRP WOW |
ID | FETCH-LOGICAL-c369t-a4e09e32c9251c424b8cbcad98c80c59a630731cb3c97a80292d1c8d561756902 |
IngestDate | Sat Nov 02 12:22:18 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Closed-loop system Type 1 diabetes Diabetic ketoacidosis SGLT2 inhibitors |
Language | English |
License | 2022 S. Karger AG, Basel. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c369t-a4e09e32c9251c424b8cbcad98c80c59a630731cb3c97a80292d1c8d561756902 |
OpenAccessLink | https://karger.com/doi/10.1159/000527653 |
PMID | 36279850 |
ParticipantIDs | pubmed_primary_36279850 |
PublicationCentury | 2000 |
PublicationDate | 2023-11-01 |
PublicationDateYYYYMMDD | 2023-11-01 |
PublicationDate_xml | – month: 11 year: 2023 text: 2023-11-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Switzerland |
PublicationPlace_xml | – name: Switzerland |
PublicationTitle | Hormone research in paediatrics |
PublicationTitleAlternate | Horm Res Paediatr |
PublicationYear | 2023 |
SSID | ssj0000387917 |
Score | 2.4517887 |
SecondaryResourceType | review_article |
Snippet | With recent developments in diabetes technology, attaining adequate glucose control is more achievable than ever. Despite these improvements, a significant... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 620 |
SubjectTerms | Adolescent Adult Blood Glucose Diabetes Mellitus, Type 1 - drug therapy Diabetic Ketoacidosis Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Sodium - therapeutic use Sodium-Glucose Transporter 2 Inhibitors - therapeutic use Symporters - therapeutic use |
Title | Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Scoping Review |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36279850 |
Volume | 96 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1NixMxGA52BellUau7rqvkIHspwZnMZCbZW6nVgugeWsFbySQpOwudKbZd8N_75mM-LIp68DKUhCnDPM-8ed7k_UDojZGwrIiEgVtCFUmZFKSg8D1meaIiAwZRu5JC80X--St_N0tnXehQN_ZfkYYxwNpmzv4D2u2fwgD8BszhCqjD9a9wX9S6PGzIhxCKPq1JV7_8G6FgEG7LonQ9dspqbN3QcTwOcTE7n6e-UD6LqnduEOTrHBRuXdlOK91uyVY23T5aeT63rRf2gQq9vdK9TX53e7NLqc1dK6Lre9dn_aMLZe_vQ9AkJOS5ZcTbThAvBDy4rG9cfbvaQKK-pcxcDtwvLDgTPuSR0TzzdYR7qG03DjZYdXPBWfTn2aNi2s3UAA1AGln1PP3UbsnZk3zwXkP9KXiQt-1jDNGj5tYj_8PpkOVjdBocCDzxyD9BD0z1FI0mldzXm-_4CruQXndWMkI3P5MBH5MBd2TAZYUtGXCMGzJc4wkOVMCeCs_Ql_ez5XROQgcNopJM7IlMTSRMQpUAGatSmhZcFUpqwRWPFBMysyY-VkWiRC55RAXVseIaRHXOMhHR5-ikAlqdIyxSreP1WnKWmtTwQoIfoIwGwR-zHETuC3TmX8tq68ukrJoXdvHbmZdo2DHpEj1cwzdoXqHBTh9eO2h-AJNuTtw |
link.rule.ids | 782 |
linkProvider | EBSCOhost |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Sodium-Glucose+Co-Transporter-2+Inhibitors+in+Type+1+Diabetes%3A+A+Scoping+Review&rft.jtitle=Hormone+research+in+paediatrics&rft.au=Hropot%2C+Tim&rft.au=Battelino%2C+Tadej&rft.au=Dovc%2C+Klemen&rft.date=2023-11-01&rft.eissn=1663-2826&rft.volume=96&rft.issue=6&rft.spage=620&rft_id=info:doi/10.1159%2F000527653&rft_id=info%3Apmid%2F36279850&rft_id=info%3Apmid%2F36279850&rft.externalDocID=36279850 |